

Biodata

Personal Particulars

- Name : Poonam Salotra
- Designation : Scientist G
- Place of work : National Institute of Pathology (ICMR),
Safdarjung Hospital Campus,
New Delhi – 110029, India
- Tel. No : 26198402, 26166124
- Fellow of the Indian National Science Academy, India (**FNA**)
- Fellow of the National Academy of Sciences, India (**FNASc**)
- Fellow of the National Academy of Medical Sciences, India (**FNAMS**).
- Fellow of The World Academy of Sciences (**FTWAS**).
- JC Bose National Fellow, 2017.

Academic Qualifications

- B.Sc. Hons (Chemistry) from Delhi University in 1974.
- M.Sc. (Biochemistry) from P.G.I., Chandigarh in 1976.
- Ph.D. from V.P. Chest Institute, Delhi University in 1980.

Professional Appointments:

- Postdoctoral Fellow at Roche Institute of Molecular Biology, Nutley, New Jersey, U.S.A. (1980).
- Research Officer at Tuberculosis Research Centre, Madras (1982).
- Principal Investigator under Young Scientists scheme of Department of Science & Technology at Centre for Biotechnology, Jawaharlal Nehru University, New Delhi (1991).
- Pool Research Officer (CSIR) at Centre for Biotechnology, Jawaharlal Nehru University, New Delhi (1993).
- Senior Research Officer at Institute of Pathology (ICMR), New Delhi (1996).
- Assistant Director at Institute of Pathology (ICMR), New Delhi (2000).
- Deputy Director at National Institute of Pathology (ICMR), New Delhi (2005).
- Sr. Deputy Director (Scientist F) at National Institute of Pathology, New Delhi (2011-2015).
- Scientist G, at National Institute of Pathology, New Delhi (2015-till date).
- Director In-Charge, National Institute of Pathology, New Delhi (2016-till date).

Research & Teaching Experience:

- 32 years of total research experience.
- 20 years of teaching experience- M.Sc. (Biotech) at Jawaharlal Nehru University, New Delhi and PhD course work at National Institute of Pathology, New Delhi.
- Chief of Molecular Biology Lab at Institute of Pathology (ICMR), since 1996.
- Chief Supervisor for 18 PhD, 2 M.Phil. students; Co-supervisor for 1 M.D. (AIIMS).

Research Interests:

Worked on the molecular basis of pathogenesis of infectious diseases including Visceral Leishmaniasis (VL), Anthrax, Tuberculosis and Cholera. Currently working on development of diagnostic tests and attenuated vaccines, mechanism of drug resistance and characterization of immune responses in patients of VL, PKDL (post kala-azar dermal leishmaniasis) and cutaneous leishmaniasis.

Awards/Honours**Fellowship of Academies**

1. Fellow of the National Academy of Medical Sciences, India (FNAMS), 2014.
2. Fellow of The World Academy of Sciences (FTWAS), 2014.
3. Fellow of the Indian National Science Academy, New Delhi, India, 2012.
4. Fellow of the National Academy of Sciences, India, 2008.

National Awards

5. J.C. Bose Fellowship- 2017
6. Drs. Kunti & Om Prakash Oration Award – 2014
7. Basanti Devi Amir Chand Award conferred by ICMR in the year 2006.
8. Prof. BK Aikat Award conferred by ICMR in 2004.
9. Kshanika Oration Award for Eminent Woman Scientist, conferred by ICMR in 2002.
10. National Science Talent Scholarship awarded by NCERT, New Delhi from 1971 to 1980.

Professional Recognition

1. Appointed member of the WHO Advisory Panel on Parasitic Diseases, 2013 to 2017.
2. Appointed member of Medical and Health Sciences Advisory Committee of the World Academy of Sciences (TWAS), 2016-2018.
3. Member of RTAG (Regional Technical Advisory Group), SEARO, WHO, 2012-2015.
4. Member, International Consortium for PKDL, since 2012.

5. Lab recognized as a **WHO Referral Centre** for confirmatory diagnosis and species identification in cases of KA and PKDL.
6. Member of WHO Expert Committee meeting on Leishmaniasis, Geneva, Switzerland, 2010.
7. Awarded ORISE Fellowship by Centre for Biologics Evaluation and Research (CBER), FDA, USA in 2010.
8. Awarded Global Health Travel award by Bill and Melinda Gates Foundation for presenting work at Keystone Symposium in Tahoe City, California, USA, 2007.
9. ICMR International Fellowship for Senior Biomedical Scientists for the year 2006.
10. Awarded Courtesy Fellowship by CBER, FDA, USA in 2005.
11. Awarded fellowship by National Foundation of Infectious Diseases, USA in 2005.
12. Granted ICMR Award for Excellent Research output in 2004.
13. Silver Jubilee award by Indian Association of Medical Microbiology in 2003.
14. Awarded Courtesy Fellowship by CBER, FDA, USA in 2003.

Patents

1. US Patent No. 6,855,522, entitled “Species-specific PCR assay for detection of *Leishmaniadonovani* in clinical samples of kala-azar and post kala-azar dermal leishmaniasis”(2002).
2. Indian patent no. 243725 for “Live attenuated *Leishmaniavaccines*” (2006).
3. US patent no. 7887812 for “Live attenuated *Leishmaniavaccines*” (2011).
4. Indian patent filed (application no. 349/DEL/2014) for “Loop mediated isothermal amplification (LAMP) assay for a reliable and rapid diagnosis of *Leishmania* infection” (2014). Published on 31/08/2016.

Membership of Professional Associations

1. Indian Society for Parasitology (Life member)
2. Society of Biological Chemists, India (Life member).
3. Association of Clinical Biochemists of India (Life member)
4. Indian Association of Medical Microbiologists (Life member)
5. Indian Immunology Society (Life member).
6. Member of Molecular Immunology Forum, India.

Membership of Advisory Boards

1. Member of TWAS Advisory Committee in Medical and Health Sciences (2016-2018).
2. Member, Advisory Committee of Shanti Swarup Bhatnagar Prize for Science and Technology in Biological Sciences, CSIR, New Delhi, 2016.
3. Member of the WHO Advisory Panel on Parasitic Diseases (Leishmaniasis) from 2013 to 2017.
4. Member of Scientific Advisory Committee (SAC) of RMRI Patna, 2016
5. Member of Project Review Committee at BIRAC, DBT, India, from 2015.
6. Member of RTAG (Regional Technical Advisory Group), SEARO, WHO, 2012- 2015.
7. Member of WHO advisory Panel on Parasitic Diseases during 2009-2013.
8. Member of Peer review committee (PRC), ECD, ICMR, from 2008 till date.
9. Member of Scientific Advisory Committee at National Institute of Communicable Diseases (NICD), Delhi, from 2003 to 2006.

Editor to Journals: Associate Editor, BMC Infectious Diseases

Invited reviewer for

1. PLoS Neglected Tropical Diseases
2. Journal of Immunology
3. Molecular and Biochemical Parasitology
4. Journal of Antimicrobial Chemotherapy
5. Antimicrobial Agents & Chemotherapy
6. Parasitology Research
7. Journal of Clinical Microbiology
8. British Journal of Dermatology
9. FEMS Microbiol Letters
11. Indian J Medical Research
12. PLoS One
13. Vaccine
14. Scientific Reports. etc.

Conferences /Meetings attended (from 2003)

International

1. Invited participant at the 13th General Conference and 26th General Meeting of The World Academy of Sciences (TWAS) at Vienna, Austria, in Nov 2015.
2. Participated and presented work on drug resistance at 5th Central European Symposium on Antimicrobials and Antimicrobial Resistance (CESAR) 2015, at Sibenik, Croatia in Sep, 2015.
3. Invited delegate and chairperson of the session on "Case detection and Surveillance" at "Kala-azar Elimination Program" partners' consultative meeting held at WHO, Geneva, Switzerland in Feb, 2015.
4. Invited speaker at the 4th PKDL Consortium meeting held at Istanbul, Turkey in Dec, 2014.
5. Invited speaker at the 3rd International Conference on Clinical Microbiology and Microbial Genomics, held at Valencia, Spain in Sep, 2014.

6. Member of 5th Regional Technical Advisory Group, WHO meeting held at Paro, Bhutan, Sep, 2013.
7. Member of Indian delegation for promoting Indo-Africa collaboration to Pasteur Institute, Tunis, Tunisia, May, 2013.
8. Invited speaker at 5th World Leishmania Congress held at Brazil, May, 2013.
9. Invited speaker at 61st Annual Meeting of American Society of Tropical Medicine and Hygiene (ASTMH), Atlanta, USA in Nov, 2012.
10. Chaired the session on Open dissemination meeting of Kaladrug-R project workshop held at Kathmandu, Nepal, Sep, 2012
11. Participated in Gordon Research Conference on Drug resistance held at USA, July, 2012.
12. Invited participant at the Workshop and Steering Committee meeting under a vaccine development project funded by European Commission held at Toulon, France in Feb, 2012.
13. Invited participant at International Symposium on Vaccines: From Discovery to Translation held at Surajkund, New Delhi, India on Nov, 2011.
14. Invited speaker at the “Advanced WHO-IRTC/UNIL course on Immunology, Vaccinology and Biotechnology applied to Leishmaniasis” at Lausanne, Switzerland in Oct, 2011.
15. Invited participant at the Workshop under a European Commission funded project on drug resistance, held at Berlin, Germany in Sep, 2011.
16. Invited participant at the Workshop at Strathclyde University, Glasgow, UK, June, 2011.
17. Presented work at 15th Annual Conference on Woods Hole Immuno-Parasitology (WHIP) conference held at MA, USA, in Apr, 2011.
18. Invited participant at the Workshop and Steering Committee meeting under a vaccine development project funded by European Commission held at Lima, Peru in Feb, 2011.
19. Participated in symposium on “Prevention, Treatment and Control of Leishmaniasis, Trypanosomiasis and Chagas disease” held at Pasteur Institute, Paris under organization by European Commission in Sept, 2010.
20. Attended the Workshop and Steering Committee meeting under a vaccine development project funded by European Commission held at Lyon, France in June, 2010.
21. Invited participant at WHO Expert committee meeting on Leishmaniasis held at Geneva in March, 2010.
22. Chaired the session on “Drug resistance and mechanism” at World *Leishmania* Congress IV held at Lucknow in Feb,2009.
23. Invited speaker in symposium on “Diagnostics and test of cure for Visceral leishmaniasis” organized by Infectious Disease Research Institute, Seattle, USA at World Leishmania Congress IV held at Lucknow in Feb,2009.
24. Gave a seminar at the Institute for Microbiology & Hygiene, Charite University, Berlin, Germany in June, 2008.
25. Invited speaker in a conference of Interdisciplinary Forum on Leishmaniasis at Heidelberg, Germany in Apr, 2008.
26. Chairperson in a conference on "Integrated functional genomics on the road to Leishmaniasis control" at Dormy House, Worcestershire, UK in Sep, 2007.

27. Presented work at meeting of Parasitology Interest Group at CBER, FDA, Bethesda, MD, USA in June, 2007.
28. Selected as ICMR International Fellow for Research at Royal Melbourne Hospital, Melbourne, Australia in Mar, 2007.
29. Participated in Keystone symposium in California, USA in Jan, 2007.
30. Invited participant at Scientists forum on "How to enhance Indo German Research Cooperation?" At German House, New Delhi in Mar, 2006.
31. Invited participant in Indo-Swedish Parasitology Meet at Goa in Dec, 2005.
32. Participated in The Eighth Annual conference on vaccine at Baltimore, USA, May, 2005.
33. Invited speaker for a round table on advances in diagnostics of Leishmaniasis at World *Leishmania* Congress at Sicily, Italy, Apr, 2005.
34. Presented paper in the 15th European Congress of Clinical Microbiology and Infectious Diseases, held at Copenhagen, Denmark, Apr, 2005.
35. Invited speaker at workshop on Intracellular pathogens sponsored by Fogarty International centre of NIH, US at India Habitat Centre, Delhi, Mar, 2005.
36. Invited participant in an Indo-German workshop on Leishmaniasis at Humboldt University, Berlin, Germany, July, 2004.
37. Presented work in Indo-German Seminarat IICB, Kolkata, Dec, 2003.
38. Participated in "The Genomic Policy Executive Course" conducted as an Indo-Canadian initiative by ICMR and the Canadian Program on Genomic and Global Health, University of Toronto, Canada, at Kochi, Kerala, Jan, 2003.

National

1. Invited participant for " Science Promotion Committee Meeting " held at Indian National Science Academy (INSA), New Delhi, Sep 2016.
2. Attended meeting on " India Africa Health Sciences meet" at Vigyan Bhawan, New Delhi in Sep, 2016.
3. Member, Advisory committee of Shanti Swarup Bhatnagar Prize for Science and Technology 2016 in Biological Sciences, CSIR, New Delhi in Sep, 2016.
4. Invited Consultant for DNDi-RMRI collaborative project on PKDL, at RMRI, Patna in June, 2016.
5. Attended and Presented work on "Diagnostics for VL and PKDL" at "Brainstorming meeting of Vector Borne Diseases Science Forum" held at ICMR, Delhi in Feb, 2016.
6. Member of Scientific Advisory Committee (SAC) of RMRI Patna in Jan, 2016
7. Invited participant at Consultative meeting of ICMR and DNDi, PHD house, Delhi Dec 2015.
8. Member of Technical Advisory Committee Meeting at Hyderabad for BIRAC project Dec, 2015.
9. Conference on "New R&D Pathways to Address Neglected Diseases' Needs in the Indian Sub-continent" organized by DNDi, New Delhi at India International Centre, New Delhi in Oct 2015.

10. Member of technical Advisory Committee Meeting at Chennai for BIRAC project June, 2015.
11. Invited member of Technical Specification Committee meeting regarding Kala-azar elimination program held at Nirman Bhawan, New Delhi, April 2015.
12. Participated in Informal Expert Consultation on Kala-azar, WHO-SEARO, Delhi, March, 2015.
13. Attended a meeting at National Institute of Immunology as a committee member for discussion of a new potential vaccine against leishmaniasis organized by DBT, New Delhi, Feb 2014.
14. Invited participant in the DBT-BCIL Mentorship Workshop for Women Scientist on "Writing Effective Scientific Proposals" at INSA, July, 2013.
15. Appointed on board of selection committee for award of INSPIRE faculty fellowship interviews held at DIPSAR, New Delhi, May 2013.
16. Invited Speaker at the Work-shop "Indo-US Vaccine Action Programme Twenty Five Year Celebration (1987-2012)" held at National Institute of Immunology, New Delhi, Sep, 2012.
17. Attended WHO Informal Consultative Meeting in preparation for PKDL case management and control guidelines held at Kolkata, India, July, 2012.
18. Invited speaker at International meeting on "Post Kala Azar Dermal Leishmaniasis" held at New Delhi, June, 2012.
19. Participated in "Molecular Diagnostics Challenges Vis-à-vis Growth Potential" meeting held at Indian Habitat Centre, New Delhi, June, 2012.
20. Invited participant in 1st Annual meeting on Kala Azar Alleviation Initiative held at Mapples Hotel, New Delhi, Mar, 2012.
21. Participant in Brain storming meeting of Vector science forum on Japanese Encephalitis and Visceral and Cutaneous Leishmaniasis held at NIP, Delhi in Feb, 2012.
22. Invited speaker in workshop on Monitoring of Clinical outcomes of Kala-Azar in the Health system & surveillance of drug resistance, held at Surajkund, Jan, 2012.
23. Invited participant Kala-azar Alleviation Initiative meeting held at Mapples Hotel, New Delhi, Mar, 2012.
24. Invited as a member of the PRC meeting on Malaria Leishmania and Filariasis held at ICMR HQ, New Delhi in 2010 and 2011.

25. Invited to attend a joint ICMR-DNDi consultation meeting on treatment options for VL in April 2010 at ICMR Hqrs. Office, New Delhi, India.
26. Participated in WHO sponsored meeting on “ An Indian innovation networking meeting to review the mapping results and discuss strategic plans for part of the proposed Asian Network for drugs and diagnostics innovation held at NII, New Delhi in Apr,2010.
27. Invited speaker at National CME Dermatology held at AIIMS, New Delhi in Apr, 2010.
28. Delivered a talk on Drug resistance in Visceral Leishmaniasis in India at 97th session of Indian Science Congress held at University of Kerala, Thiruvananthapuram in Jan, 2010.
29. Invited participant at workshop on Policy issues in Kala azar held in New Delhi in Nov, 2009.
30. Participated inMolecular Immunology Forum meeting at Alibagh, Mumbai,Mar, 2009.
31. Delivered a talk at CDRI, Lucknow in Dec, 2008.
32. Invited speaker at ACBICON held at New Delhi in Dec, 2007.
33. Invited speaker at WHO-GTZ sponsored workshop at Taj Ganges, Varanasi in Apr, 2007.
34. Invited speaker in Annual meeting of Biomedical Scientists at Kerala University, Nov, 2006.
35. Invited speaker in Medical Development Congress at Assocham House, Delhi in Sep, 2006. Participated in a Workshop on “Ethical Review for Protection of Human Participants involved in Research” organized by ICMR and sponsored by Fogarty, NIH, USA, held at Assocham House, New Delhi in Apr, 2006.
36. Invited participant in technical consultation on National Vector borne Disease Control program at National Agriculture Science Complex in Mar, 06.
37. Invited speaker at Molecular Immunology Forum organized by Regional Medical Research Centre(ICMR) Bhubaneswar, in Jan, 2006.
38. Participated in 32nd annual conference of AssocClinBiochem India, Patna, in Dec, 2005.
39. Invited speaker in 32nd Meet of Indian Immunology Society at PGI, Chandigarh, Nov, 2005.
40. Presented work at Saha Institute of Nuclear Physics, Kolkata in Jan, 2005.
41. Invited speaker at meeting organized by Bill and Melinda Gates foundation to discuss Visceral Leishmaniasis elimination program in South Asia at Hotel Taj, New Delhi in Jan, 2005.
42. Presented paper inSirDorabji Tata Symposium at Bangalore, Mar, 2004.
43. Presented work at Annual meet of Indian Association of Medical Microbiologists at Mumbai, Nov,2003.
44. Presented paper in 29th Annual Conference of Association of Clinical Biochemists of India at Jaipur, in Feb, 2003.

Extramural funded projects:

1. Principal investigator in the Project funded by **ICMR** entitled “Evaluation of immune status and parasite load in patients of post kala-azar dermal leishmaniasis in response to treatment with miltefosine and amphotericin B.” (2017-2020).
2. Principal investigator in the Project funded by **ICMR** entitled "Investigations on paromomycin resistance in *Leishmaniadonovani* using molecular and biochemical tools" (2015-2018).
3. Co-investigator in the Project funded by **ICMR** entitled "Identification and characterization of artemisinin resistance associated genes in *Leishmania*". (2015-2018).
4. Principal investigator in the Project funded by **DBT** entitled “Development of new live attenuated vaccinecandidates for kala-azar” (2011-2015).
5. Principal investigator in the Project funded by **DBT** entitled “Protective immunogenicity of Centrin KO live attenuated *Leishmania* parasite in the animal models and in the human cells” (2011-2014).
6. Principal investigator in the Project funded by **European Commission** entitled ” New tools for monitoring drug resistance and treatment response in Visceral Leishmaniasis in the Indian subcontinent” (2009-2013).
7. Principal investigator (India) in the Project funded by **European Commission** entitled ”Pre-clinical studies of a PSA based human vaccine candidate targeting visceral , cutaneous and muco- cutaneous Leishmaniasis and Development of the associated procedures for further clinical trials” (2009-2012).
8. Principal Investigator in project funded by **ICMR** entitled “Transcriptome Profiling for identification and characterization of Miltefosine resistance associated genes of *Leishmaniadonovani*”. (2009-2012).
9. Principal Investigator in project entitled “Parasite surface antigen-2(PSA-2) of *Leishmaniadonovani*: studies on its role in parasite virulence, drug resistance and modulation of host macrophage function” funded by **Department of Science and Technology** (2008-2011).
10. Principal Investigator in project funded by **ICMR** entitled “Analysis of host immuno-determinants involved in the pathogenesis of Indian Cutaneous Leishmaniasis exploiting cDNA microarray” (2007-2010).
11. Principal Investigator in project funded by **Ministry of Defence** entitled” Evaluation of Host immunodeterminants involved in the pathogenesis of kala azar and Post Kala azar Dermal Leishmaniasis using cDNA array” (2006-2009).
12. **Indo-German** project entitled “Molecular Characterization of *Leishmania* Parasites Isolated from Dermal Lesions of PKDL patients in India” funded by Department of Science and Technology. (2005-2008).

13. Principal Investigator in project funded by **Indo-US Vaccine Action Program** on “Discovery of virulence-related genes in *Leishmaniadonovani* using a genomic microarray” (2004 to 2007).
14. Principal Investigator in project funded by **Department of Science and Technology** on “Molecular cloning of differentially expressed genes in *Leishmaniadonovani* isolated from patients of post kala-azar dermal leishmaniasis” (2003-2006).
15. Principal Investigator in project on “Evaluation of cellular immune responses in kala-azar and PKDL” funded by **DRDO**, Ministry of Defence (2002-2005).
16. Principal Investigator in **ICMR** Task-force approved project on Application of DNA microarray technology for identification of differentially expressed genes in parasite isolates from Kala-azar and PKDL patients (2002-2005).
17. Principal Investigator in project funded by **Indo-US Vaccine Action Program** on “Identification and characterization of genes with stage specific expression in *Leishmaniadonovani* isolated from kala-azar patients” (1999 to 2003).
18. Co-investigator in project funded by **Department of Biotechnology** on “Cloning and expression of a mutagenized variant of protective antigen” (1995 to 1998).
19. Co-investigator in project entitled “Production of a recombinant vaccine against anthrax” funded by **Ministry of Defence** (1995 to 1998).
20. Co-investigator in **DAE** (Department of Atomic Energy) project entitled “Development of an immunotoxin against filariasis” (1994 to 1996).
21. Principal investigator in **DST** (Department of Science & Technology) project entitled “Role of stress proteins in *Leishmania*” (1991 to 1993).

List of Publications

In Journals included on Medlar

1. Avishek K, Kaushal H, Gannavaram S, Dey R, Selvapandiyan A, Ramesh V, Negi NS, Dubey US, Nakhasi HL, **Salotra P**. Gene deleted live attenuated *Leishmania* vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs. **Sci. Rep.** 6, 33059; doi: 10.1038/srep33059 (2016).
2. Gannavaram S, Bhattacharya P, Dey R, Ismail N, Avishek K, **Salotra P**, Selvapandiyan A, Satoskar A, Nakhasi HL. Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated *Leishmania* Parasite Vaccines. **Methods Mol Biol.** 1403:623-638 (2016).
3. Kaushal H, Bras-Gonçalves R, Avishek K, Deep DK, Petitdidier E, Lemesre JL, Papierok G, Kumar S, Ramesh V, **Salotra P**. Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of Post Kala-Azar Dermal Leishmaniasis in India. **ClinExpImmunol.** 185(1):50-60 (2016).
4. Sharma V, Sharma P, Selvapandiyan A, **Salotra P**. Ubiquitin related modifier-1 (LdUrm1): an early endosome associated ubiquitin like conjugation in *Leishmaniadonovani*. **MolMicrobiol.** 99(3):597-610 (2016).
5. Ramesh V, R. Singh, Kumar A, Verma A, Deep DK, Verma S and **Salotra P**. Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India. **PLoS Negl Trop Dis** 22; 9(10):e0004093 (2015).
6. Ramesh V, Kaushal H, Mishra AK, Singh R and **Salotra P**. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study. **BMC Public Health** 15:1092 (2015).
7. Ramesh V, Avishek K, **Salotra P**. Post-kala-azar dermal leishmaniasis in HIV-coinfected individuals: problems in diagnosis and treatment. **Int J Dermatol.** 54:116-120 (2015).
8. Kaushal H, Bras-Gonçalves R, Negi NS, Lemesre JL, Papierok G, **Salotra P**. Role of CD8+ T cells in protection against *Leishmaniadonovani* infection in healed Visceral Leishmaniasis individuals. **BMC Infect Dis.** 14:653 (2014).
9. Agrawal S, Khandelwal K, Bumb RA, Oghumu S, **Salotra P**, Satoskar AR. Pediatric cutaneous leishmaniasis in an endemic region in India. **Am J Trop Med Hyg.** 91(5):901-904 (2014).
10. Gannavaram S, Dey R, Avishek K, Selvapandiyan A, **Salotra P**, Nakhasi HL. Biomarkers of safety and immune protection for genetically modified live attenuated *Leishmania* vaccines against visceral leishmaniasis - Discovery and Implications. **Front Immunol.** 23;5:241 (2014).
11. Selvapandiyan A, Dey R, Gannavaram S, Solanki S, **Salotra P**, Nakhasi HL. Generation of growth arrested *Leishmania* amastigotes: A tool to develop live attenuated vaccine candidates against visceral leishmaniasis. **Vaccine.** 32(31):3895-3901 (2014).

12. Bhandari V, Sundar S, Dujardin JC, **Salotra P**. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in *Leishmaniadonovani*. **Antimicrob Agents Chemother**.58(5):2580- 2585 (2014).
13. Kulshrestha A, Sharma V, Singh R, **Salotra P**.Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant *Leishmaniadonovani*.**Parasitol Res**. 113(3):1171-1184 (2014).
14. Chamakh-Ayari R, Bras-Gonçalves R, Bahi-Jaber N, Petitdidier E, Markikou-Ouni W, Aoun K, Moreno J, Carrillo E, **Salotra P**, Kaushal H, Negi NS, Arevalo J, Falconi-Agapito F, Privat A, Cruz M, Pagniez J, Papierok GM, Rhouma FB, Torres P, Lemesre JL, Chenik M, Meddeb-Garnaoui A. *In vitro* evaluation of a soluble *Leishmania* promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.**PLoS One**. 9(5):e92708 (2014).
15. Krayter L, Bumb RA, Azmi K, Wuttke J, Malik MD, Schnur LF, **Salotra P**, Schönian G. Multilocus microsatellite typing reveals a genetic relationship but, also, genetic differences between Indian strains of *Leishmaniatropica* causing cutaneous leishmaniasis and those causing visceral leishmaniasis.**Parasit Vectors**. 7(1):123 (2014).
16. Ramesh V, Avishek K, Sharma V and **Salotra P**. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: A preliminary report.**ActaDermVenereol**. 94(2):242-243 (2014).
17. Katara GK, Raj A, Kumar R, Avishek K, Kaushal H, Ansari NA, Bumb RA and **Salotra P**. Analysis of localized immune responses reveals presence of Th17 and Treg cells in cutaneous leishmaniasis due to *Leishmaniatropica*. **BMC Immunol**. 14(1):52 (2013).
18. Bhandari V, Kumar D, Verma S, Srividya G, Negi NS, Singh R and **Salotra P**. Increased parasite surface antigen-2 expression in clinical isolates of *Leishmaniadonovani* augments antimony resistance. **BiochemBiophys Res Commun**. 440(4):646-651(2013).
19. Prajapati VK, Sharma S, Rai M, Ostyn B, **Salotra P**, Vanaerschot M, Dujardin JC and Sundar S. In vitro susceptibility of *Leishmaniadonovani* to miltefosine in Indian visceral leishmaniasis. **Am J Trop Med Hyg**. (4):750-754 (2013).
20. Aara N, Khandelwal K, Bumb RA, Mehta RD, Ghiya BC, Jakhar R, Dodd C, **Salotra P** and Satoskar AR. Clinco-epidemiologic study of cutaneous leishmaniasis in Bikaner, Rajasthan, India.**Am J Trop Med Hyg**. 89(1):111-115 (2013).
21. Bumb RA, Prasad N, Khandelwal K, Aara N, Mehta RD, Ghiya BC and **Salotra P**, Wei L, Peters S and Satoskar AR. Long-term efficacy of a single-dose Radio Frequency Heat therapy versus intralesionalantimonials for cutaneous leishmaniasis in India. **Br J Dermatol**. 168(5):1114-1119 (2013).
22. Cruz I, Millet A, Carrillo E, Chenik M, **Salotra P**, Verma S, Veland N, Jara M, Adaui V, Castrillón C, Arévalo J, Moreno J and Cañavate C. An approach for interlaboratory comparison of conventional and real-time PCR assays for diagnosis of human leishmaniasis. **ExptParasitol**. 134(3): 281-289 (2013).

23. Verma S, Avishek K, Sharma V, Negi NS, Ramesh V and **Salotra P**. Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. **Diagn Microbiol Infect Dis**. 74(4):390-395 (2013).
24. Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S and **Salotra P**. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of *Leishmaniadonovani*. **Parasitol Res**. 112(2):825-828 (2013).
25. Verma S, Bhandari V, Avishek K, Ramesh V and **Salotra P**. Reliable diagnosis of PKDL using slit aspirate specimen to avoid invasive sampling procedures. **Trop Med Int Health**. 18(3):268-275 (2013).
26. Dey R, Dagur PK, Selvapandiyani A, McCoy JP, **Salotra P**, Duncan R and Nakhasi HL. Live Attenuated *Leishmaniadonovani* p27 Gene Knockout parasites are nonpathogenic and elicit long-term protective immunity in Balb/c mice. **J Immunol**. 190(5):2138-2149 (2013).
27. Gannavaram S, Connelly PS, Daniels MP, Duncan R, **Salotra P** and Nakhasi HL. Deletion of mitochondrial associated ubiquitin fold modifier protein Ufm1 in *Leishmaniadonovani* results in loss of β -oxidation of fatty acids and blocks cell division in the amastigote stage. **Mol Microbiol**. 86(1):187-198 (2012).
28. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC and **Salotra P**. Drug susceptibility in *Leishmania* Isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. **PLoS Negl Trop Dis**. 6(5) e1657 (2012).
29. Subba Raju BV, Gurumurthy S, Kuhls K, Bhandari V, Schonian G and **Salotra P**. Genetic typing reveals monomorphism between antimony sensitive and resistant *Leishmaniadonovani* isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India. **Parasitol Res**. 111(4):1559-1568 (2012).
30. Katara GK, Ansari NA, Ramesh V and **Salotra P**. Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL). **PLoS Negl Trop Dis**. 6(6):e1703 (2012).
31. Hendrickx S, Inocência da Luz, RA, **Salotra P**, Carter K, Dujardin JC, Cos P and Maes L. Experimental induction of paromomycin resistance in antimony-resistant strains of *L. donovani*: outcome dependent on selection protocol. **PLoS Negl Trop Dis**. 6(5): e1664 (2012).
32. Kumar D, Singh R, Bhandari V, Kulshrestha A, Negi NS and **Salotra P**. Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of *Leishmaniadonovani*. **Parasitol Res**. 111(1):223-230 (2012).
33. Srividya G, Kulshrestha A, Singh R and **Salotra P**. Diagnosis of visceral leishmaniasis: developments over the last decade. **Parasitol Res**. 110:1065-1078 (2012).
34. Selvapandiyani A, Dey R, Gannavaram S, Lakhal-Naouar I, Duncan R, **Salotra P** and Nakhasi HL. Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. **J Trop Med**. 631460 Sep (2012).

35. Ramesh V, Katara GK, Verma S and **Salotra, P.** Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. **Br J Dermatol.** 165: 411–414 (2011).
36. Prasad N, Ghiya B, Kaushal H, Satoskar AA, Davila Claudio L, **Salotra P,** Bumb RA and Satoskar AR. Heat, Oriental sore and HIV. **The Lancet** 377: 610 (2011).
37. Sreenivas G, Sharma P, Duncan R, **Salotra P** and Nakhasi HL. Mitochondrial associated Ubiquitin fold modifier-1 mediated protein conjugation in *Leishmaniadonovani*. **PLoSOne** 6 (1):e16156(2011).
38. Soni P, Prasad N, Khandelwal K, Ghiya B, Mehta R, Bumb RA and **Salotra P.** Unresponsive cutaneous leishmaniasis and HIV coinfection: Report of three cases. **Ind J DermatolVenereolLeprol.** 77(2) (2011).
39. Kulshrestha A, Singh R, Kumar K, Negi NS and **Salotra P.** Antimony resistant clinical isolates of *Leishmaniadonovani* are susceptible to paromomycin and sitamaquine. **Antimicrob Agents Chemother.** 55(6)2916-2921 (2011).
40. Katara GK, Ansari NA, Verma S, Ramesh V and **Salotra P.** Foxp3 and IL -10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. **PLoS Neg Trop Dis.** 5(5) e1171 (2011).
41. Khandelwal K, Bumb RA, Mehta RD, Kaushal H, Lezama-Davila C, **Salotra P** and Satoskar AR. A patient with diffuse cutaneous leishmaniasis as a first indicator of HIV infection in India. **Am J Trop Med Hyg.** 85(1):64-65 (2011).
42. Dey R, Meneses C, **Salotra P,** Kamhawi S, Nakhasi HL and Duncan R. Characterization of a *Leishmania* stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence. **MolMicrobiol.** 77(2):399-414 (2010).
43. Singh R, Kumar D, Duncan RC, Nakhasi HL and **Salotra P.** Overexpression of Histone H2A modulates drug susceptibility in *Leishmania* parasites. **Int. J. Antimicrob. Agents.** 36; 50-57 (2010).
44. Sharma P, Gurumurthy S, Duncan R, Nakhasi HL and **Salotra P.** Comparative in vivo expression of amastigote up regulated *Leishmania* genes in three different forms of Leishmaniasis. **Parasitol Int.** 59: 262–264 (2010).
45. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V and **Salotra P.** Quantification of parasite load in clinical samples of Leishmaniasis patients: IL-10 Level correlates with parasite load in Visceral Leishmaniasis. **PLoS One** 5(4): e10107 (2010).
46. Ramesh V, Kumar J, Kumar D and **Salotra P.** A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis. **Ind J DermatolVenereolLeprol.** 76(2):138-144 (2010).
47. Kumar R, Bumb RA and **Salotra P.** Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by *Leishmaniatropica*: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors. **Immunology** 130:193–201 (2010).

48. Kumar D, Ramesh V, Verma S, Ramam M and **Salotra P**. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and Miltefosine. **Ann Trop Med Parasitol**. 103: 727-730 (2009).
49. Kumar R, Bumb RA and **Salotra P**. Correlation of parasitic load with interleukin-4 response in patients with cutaneous leishmaniasis due to *Leishmaniatropica*. **FEMS Immunol Med Microbiol**. 57(3):239-246 (2009).
50. Kumar D, Kulshrestha A, Singh R and **Salotra P**. *In vitro* susceptibility of field isolates of *Leishmaniadonovani* to Miltefosine and Amphotericin B: correlation with SAG susceptibility and implications for treatment in the endemic area. **Antimicrob Agents Chemother**. 53:835-838 (2009).
51. Alam MZ, Kuhls K, Schweynoch C, Sundar S, Rijal S, Shamsuzzaman AK, Raju BV, **Salotra P**, Dujardin JC and Schönian G. Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of *Leishmaniadonovani* strains in the Indian subcontinent **Infect Genet Evol**.; 9:24-31(2009).
52. Sethuraman G, SharmaVK and **Salotra P**. Indian mucosal leishmaniasis due to *Leishmaniadonovani*. **New Engl J Med**. 358(3):313-315 (2008).
53. Ansari NA, Katara GK, Ramesh V and **Salotra P**. Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis. **ClinExpImmunol**. 154(3):391-398 (2008).
54. Ansari NA, Ramesh V and **Salotra P**. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis. **Trans R Soc Trop Med Hyg**. 102 (11):1160-1162 (2008).
55. Kumar R, Ansari NA, Avninder S, Ramesh V and **Salotra P**. Cutaneous Leishmaniasis in Nepal: *L. major* is a cause. **Trans Roy Soc Trop Med Hyg**.102: 618-619(2008).
56. Subba Raju BV, Singh R, Sreenivas G, Singh Sand **Salotra P**. Genetic fingerprinting and identification of differentially expressed genes in isolates of *Leishmaniadonovani* from Indian patients of post-kala-azar dermal leishmaniasis. **Parasitology**135(1):23-32 (2008).
57. Ramesh V, Ansari NA and **Salotra P**. Oral miltefosine in the treatment of Post-kala-azar Dermal Leishmaniasis. **ClinExpDermatol**.33(1):103-115 (2008).
58. Kumar R, Ansari NA, Singh A, Ramesh V and **Salotra P**. Cutaneous Leishmaniasis in Nepal: *Leishmania major* is a cause. **Trans Roy Soc Trop Med Hyg**.102(2):202-203 (2008).
59. Kumar D, Srividya G, Verma S, Singh R, Negi NS, Fragaki K, Kubar J and **Salotra P**. Presence of anti Lepp12 antibody: a marker for diagnostic and prognostic evaluation of visceral leishmaniasis, **Trans Roy Soc Trop Med Hyg**.102(2):167-171 (2008).
60. Ramesh V, Ramam M, Singh R and **Salotra P**. Hypopigmented post-kala-azar dermal leishmaniasis. **Int J Dermatol**.47: 414-416 (2008).
61. Selvapandiyan A, Duncan R, Mendez J, Kumar R, **Salotra P**, Cardo LJ and Nakhasi HL. A *Leishmaniaminircle* DNA footprint assay for sensitive detection and rapid speciation of clinical isolates. **Transfusion** 48: 1787-1798 (2008).

62. Ansari NA, Kumar R, Raj A and **Salotra P**. Elevated levels of IgG3 and IgG4 subclass in paediatric cases of kala azar. **Parasite Immunol.** 30:403-409 (2008).
63. Kumar R, Bumb RA, Ansari NA, Mehta RD and **Salotra P**. Cutaneous leishmaniasis caused by *Leishmaniatropica* in Bikaner, India: Parasite identification and characterization using molecular and immunological tools. **Am J Trop Med Hyg.** 76:896-901 (2007).
64. Srividya G, Duncan R, Sharma P, Subbaraju BV, Nakhasi HL and **Salotra P**. Transcriptome analysis during the process of in vitro differentiation of *Leishmania donovani* using genomic microarrays. **Parasitology** 134:1527-1539 (2007).
65. Ramesh V, Singh R and **Salotra P**. Post kala-azar dermal leishmaniasis-an appraisal. **Trop Med & Int Health** 12(7):848-851 (2007).
66. Ramesh V, Kataria J and **Salotra P**. An unusual presentation of Post-kala-azar dermal Leishmaniasis. **Trop Doctor** 37(3):172-173 (2007).
67. Ansari NA, Sharma P and **Salotra P**. Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: Correlation with clinical outcome. **ClinImmunol.** 122:343-348 (2007).
68. Ansari NA, Ramesh V and **Salotra P**. IFN- γ , TNF- α , IL-6 and IFN- γ R1 are the major immunologic determinants associated with Post kala azar dermal leishmaniasis. **J Infect Dis.** 194: 958-965 (2006).
69. Singh R, Kumar D, Ramesh V, Negi NS, Singh S and **Salotra P**. Visceral Leishmaniasis or kala Azar: High incidence of antimony refractoriness in Indian Kala azar is contributed by anthroponotic transmission via Post kala azar dermal leishmaniasis. **J Infect Dis.** 194: 302-306 (2006).
70. Ansari NA, Saluja S and **Salotra P**. Elevated levels of Interferon- γ , Interleukin-10 and Interleukin-6 during active disease in Indian kala azar. **ClinImmunol.** 119 (3):339-345 (2006).
71. **Salotra P**, Duncan RC, Singh R, Subba Raju BV, Sreenivas G and Nakhasi HL. Up regulation of surface proteins in Leishmaniadonovani isolated from patients of Post Kala-azar Dermal Leishmaniasis (PKDL). **Microbes & Infection** 8(3): 637-644 (2006).
72. **Salotra P** and Singh R. Challenges in the diagnosis of Post Kala Azar Dermal Leishmaniasis (PKDL). **Ind J Med Res.** 123: 295-310 (2006).
73. Selvapandiyam A, Duncan R, Debrabant A, Lee N, Sreenivas G, **Salotra P** and Nakhasi HL. Genetically modified live attenuated parasites as vaccines for leishmaniasis. **Ind J Med Res.** 123: 455-466 (2006).
74. Singh R, Subba Raju BV, Jain RK and **Salotra P**. Potential of Direct Agglutination Test (DAT) based on promastigote and amastigote antigens for serodiagnosis of Post Kala Azar Dermal Leishmaniasis. **ClinDiag Lab Immunol.** 12(10):1191-1194 (2005).
75. Maurya R, Singh RK, Kumar B, **Salotra P**, Rai M and Sundar S. Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure. **J ClinMicrobiol.** 43(7):3038-3041 (2005).
76. Selvapandiyam A, Stabler K, Ansari NA, Kerby S, Riemenschneider J, **Salotra P**, Duncan R and Nakhasi HL. Novel semiquantitative fluorescence-based multiplex PCR Assay for simultaneous detection of bacterial and parasitic pathogens. **J Mol Diag.** 7: 268-275 (2005).

77. **Salotra P**, Singh R, Duncan R and Nakhasi HL. Microarray based analysis of gene expression in drug resistant *Leishmaniadonovani* isolated from Kala azar. **Clin. Microbiol. Infect.** 11:S2-47-48 (2005).
78. **Salotra P** and Singh R. Rapid and reliable diagnostic tests for visceral leishmaniasis. **Ind J Med Res.** 122:464-467 (2005).
79. Selvapandiyan A, Debrabant A, Duncan R, Muller J, **Salotra P**, Sreenivas G, Salisbury JL and Nakhasi HL. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in *Leishmania*. **J Biol Chem.** 279:25703-25710 (2004).
80. Sreenivas G, Nasim AA, Joginder K and **Salotra P**. Nested-PCR assay for detection of *Leishmaniadonovani* in slit aspirates from Post kala-azar dermal leishmaniasis lesions. **J ClinMicrobiol.** 42:1777-1778 (2004).
81. Sreenivas G, Subba Raju BV, Singh R, Selvapandiyan A, Duncan R, Sarkar D, Nakhasi HL and **Salotra P**. DNA polymorphism assay distinguishes isolates of *Leishmaniadonovani* that cause Kala-azar from those that cause Post kala azar dermal leishmaniasis. **J ClinMicrobiol.** 42:1739-1741 (2004).
82. Khandpur S, Ramam M, Sharma VK, **SalotraP**, Singh MK and Malhotra A. Nerve involvement in Indian Post kala-azar dermal leishmaniasis. **ActaDermVenereol.** 84:1-3 (2004).
83. Sreenivas G, Singh R, Selvapandiyan A, Negi NS, Nakhasi HL and **Salotra P**. Arbitrary-primed PCR for genomic fingerprinting and identification of differentially regulated genes in Indian isolates of *Leishmaniadonovani*. **ExpParasitol.** 106:110-118 (2004).
84. Duncan R, **Salotra P**, Goyal N, Akopyants N, BeverleySM and Nakhasi HL. The application of gene expression microarray technology to kinetoplastid research. **CurrMol Med.** 4:611-621 (2004).
85. **Salotra P**, Sreenivas G, Beena KR, Mukherjee A and Ramesh V. Parasite detection in patients with Post Kala-azar Dermal Leishmaniasis: a comparison of molecular and immunological methods. **J Clin Path.** 56(11):840-843 (2003).
86. Malla N, Sengupta C, Dubey ML, Sud A, Ansari NA and **Salotra P**. Antigenaemia and antibody response to *Leishmaniadonovani* stage-specific antigens and rk39 antigen in human immunodeficiency virus-infected patients. **Br J Biomed Sci.** 60(4):210-216 (2003).
87. **Salotra P**, Sreenivas G, Ansari NA, Subba Raju BV and Ramesh V. Evaluation of ELISA for diagnosis of PKDL using crude and recombinant k39 antigen. **ClinDiag Lab Immunol.** 9(2): 370-373 (2002).
88. Sreenivas G, Ansari NA, Singh R, Subba Raju BV, Bhateja R, Negi NS and **Salotra P**. Diagnosis of visceral leishmaniasis: Comparative potential of amastigote antigen, recombinant antigen and PCR. **Br J Biomed Sci.** 59(4):218-222 (2002).
89. Selvapandiyan A, Duncan R, Debrabant A, Bertholet S, Sreenivas G, Negi NS, **Salotra P** and Nakhasi H L. Expression of a mutant form of *Leishmaniadonovani* Centrin reduces the growth of the parasite. **J Biol Chem.** 276 (46):43253-43261 (2001).
90. **Salotra P**, Sreenivas G, Sundar S and Ramesh V. A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis. **Br J Dermatol.** 145 (4): 630-632 (2001).

91. **Salotra P**, Sreenivas G, Pogue GP, Lee N, Nakhasi HL, Ramesh V and Negi NS. Development of a species-specific PCR assay for detection of *Leishmaniadonovani* in clinical samples of kala-azar and post kala-azar dermal leishmaniasis. **J ClinMicrobiol.** 39: 849-854 (2001).
92. **Salotra P**, Ralhan R and Sreenivas G. Heatstress induced modulation of protein phosphorylation in virulent promastigotes of *Leishmaniadonovani*. **Int J Biochem Cell Biol.** 32: 309-316 (2000).
93. Adhuna, **Salotra P** and Bhatnagar R. Nitric oxide induced expression of stress proteins in virulent and avirulent promastigotes of *Leishmaniadonovani*. **Immunol Lett.** 71:716-721 (2000).
94. **Salotra P**, Raina A and Ramesh V. Western blot analysis of humoral immune response to antigens of *Leishmaniadonovani* in patients of PKDL. **TransR Soc Trop Med Hyg.** 93:98-101 (1999).
95. Rao CM, **Salotra P** and Datta K. Possible role of the 34-kilodalton hyaluronic acid-binding protein in visceral leishmaniasis. **J Parasitol.** 85: 682-687 (1999).
96. **Salotra P**, Raina A and Negi NS. Immunoblot analysis of antibody response to antigens of *Leishmaniadonovani* in Indian kala-azar. **Br J Biomed Sci.** 56: 263-267 (1999).
97. Ramesh V, Misra RS, Khunger N, Beena KR, **Salotra P** and Mukherjee A. Shave excision as an adjunct to the therapy of a rhinophyma-like complication in PKDL. **ActaDermVenereol.** 79:330-331 (1999).
98. Adhuna, **Salotra P**, Mukhopadhyay B and Bhatnagar R. Modulation of macrophage heat shock protein expression in response to intracellular infection by virulent and avirulent strains of *Leishmaniadonovani*. **BiochemMol BioInt.** 43:1265-1275 (1997).
99. Ralhan R, Narayan M, **Salotra P**, Shukla NK and Chauhan S. Evaluation of p-glycoprotein expression in human oral oncogenesis: correlation with clinico-pathological features. **Int J Cancer.** 72:728-734 (1997).
100. Radha S, **Salotra P**, Bhat R and Bhatnagar R. Thermostabilization of protective antigen-the binding component of anthrax lethal toxin. **J Biotech.** 50:235-242 (1996).
101. **Salotra P**, Chauhan D, Ralhan R and Bhatnagar R. TNF-alpha induced preferential expression of stress proteins in virulent promastigotes of *Leishmaniadonovani*. **Immunol Lett.** 44:1-5 (1995).
102. **Salotra P**, Seal KP, Krishna N, Jaffe H and Bhatnagar R. Expression of DnaK and GroEL homologs of *Leuconostocmesenteroides* in response to heat shock, cold shock or chemical stress. **FEMS Microbiol Lett.** 131:57-62 (1995).
103. Richa S, **Salotra P**, Bhatnagar R and Datta K. L-alanine- dioxovalerate transaminase in *Leishmaniadonovani* that differs from the mammalian enzyme. **Microbiol Res.** 151:1-5 (1995).
104. **Salotra P**, Ralhan R and Bhatnagar R. Differential expression of stress proteins in virulent and attenuated promastigotes of *Leishmaniadonovani*. **BiochemMol Biol Intl.** 33:691-697 (1994).
105. Lai CY, Xia QC and **Salotra P**. Location and amino acid sequence around the ADP-ribosylation site in the cholera toxin active subunit A. **BiochemBiophys Res Commun.** 116:341-348 (1983).

106. **Salotra PT** and Singh VN. Regulation of glucose metabolism in rat lung: subcellular distribution, isozyme pattern and kinetic properties of hexokinase. **Arch BiochemBiophys.** 216:758-764 (1982).
107. **Salotra PT** and Singh VN. Regulation of glucose metabolism in lung: hexokinase catalyzed phosphorylation a rate limiting step. **Life Sciences** 31:791-794, (1982).
108. **Salotra PT** and Khuller GK. Lipids of *Streptomyces griseus*. **Ind J BiochemBiophys.** 14:72-74 (1977).
109. **Salotra PT** and Khuller GK. Effect of age on major phospholipids of *Streptomyces griseus*. **Ind J BiochemBiophys.** 14:85-86 (1977).

Chapters in Books/Volume of Proceedings

1. **Salotra, P.** Kaushal, H. Ramesh, V. Containing Post Kala-Azar Dermal Leishmaniasis (PKDL): Pre-requisite for Sustainable Elimination of Visceral Leishmaniasis (VL) from South Asia. Kala Azar in South Asia. Published by Springer International Publishing. PP 7-21 (2016).
2. Gannavaram ,S. Bhattacharya, P. Dey, R. Ismail, N. Avishek, K. **Salotra, P.** Selvapandiyan, A. Satoskar, A. Nakhasi, HL. Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated Leishmania Parasite Vaccines. Edited by John M. Walker. Published by Springer Protocols; Humana Press. Methods Mol Biol. 1403:623-638 (2016).
3. **Salotra, P.** Singh, R Seifert, Karin. Visceral leishmaniasis –current treatments and needs. *In* Trypanosomatid Diseases: Molecular Routes to Drug Discovery, First edition. Edited by T. Jäger, O. Koch, and L. Flohé. Published by Wiley-VCH Verlag GmbH & Co. UK, PP 5-15 (2013).
4. Singh R, Kulshrestha A, **Salotra P.** Research in diagnostic tools: the past, present and future. In “Kala azar- Emerging perspectives and prospects in South Asia”, Ed. H.P Thakur, Mittal publishers India PP 155-189 (2011).
5. Kumar D, Kulshrestha A, Singh R, **Salotra P.** *In vitro* susceptibility of Indian kala-azar isolates to Miltefosine and expression analysis of markers of drug resistance. *In* “Antimicrobial Resistance- the Modern Epidemic: Current Status and Research Issues”, Eds D. Raghunath, Nagaraja V and C.D. Rao, Macmillan publishers India Ltd. PP 406-407 (2009).
6. Ramesh V, Kumar D, **Salotra P.** Antimonial Therapy in Post-kala-azar dermal Leishmaniasis-A Hobson’s choice. In “Drugs and Pharmaceuticals- Current R & D Highlights” Eds S. Tandon and S. Mehrotra, Publisher Central Drug Research Institute, Lucknow. PP 7-10 (2008).
7. **Salotra P,** Selvapandiyan, A., Sreenivas, G., Nakhasi, H.L. Gene Knock out mutants of Leishmania as potential vaccine candidates. In “Trends and Research in Leishmaniasis” Volume 5 series of “Status Report on Tropical Diseases in India”. Eds D. Raghunath and R. Nayak, Bangalore, PP 265-286 (2005).
8. Sreenivas G, Nasim NA, Joginder K, Ramesh V, **Salotra P.** Evaluation of PCR and ELISA for diagnosis of post kala azar dermal leishmaniasis. In “Strategies for control of Kala azar and Malaria”, Proceedings of WHO workshop. Ed. S.K. Bhattacharya, New Delhi, PP 51-59 (2001).

9. **Salotra P**, Bhatnagar R. Role of stress proteins in *Leishmania*. Chapter in book “Microbes: For Health, Wealth & Sustainable Environment”. Malhotra Publishing House, New Delhi. PP. 595-615 (1998).
10. Narayanan M, Kaur J, **Salotra P** (1994). Chauhan S.S. and Ralhan R. Multidrug resistance in human oral cancer is mediated by multidrug transporter. Proc. Intl. Cancer Congress, Eds. Rao, R.S., Deo, M.G. and Singhvi, L.D., Monduzzi Editore, Bologna, Italy. Vol. 2, PP. 975-979.

